Wen‐Chien Chou

11.1k total citations · 1 hit paper
216 papers, 5.6k citations indexed

About

Wen‐Chien Chou is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Wen‐Chien Chou has authored 216 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Hematology, 70 papers in Molecular Biology and 62 papers in Genetics. Recurrent topics in Wen‐Chien Chou's work include Acute Myeloid Leukemia Research (104 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (47 papers) and Semiconductor Quantum Structures and Devices (32 papers). Wen‐Chien Chou is often cited by papers focused on Acute Myeloid Leukemia Research (104 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (47 papers) and Semiconductor Quantum Structures and Devices (32 papers). Wen‐Chien Chou collaborates with scholars based in Taiwan, United States and United Kingdom. Wen‐Chien Chou's co-authors include Hwei‐Fang Tien, Hsin‐An Hou, Jih‐Luh Tang, Ming Yao, Woei Tsay, Shang‐Yi Huang, Chien‐Yuan Chen, Chi V. Dang, Mei‐Hsuan Tseng and Shang‐Ju Wu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Physical Review Letters and Journal of Clinical Investigation.

In The Last Decade

Wen‐Chien Chou

203 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wen‐Chien Chou Taiwan	39	3.2k	2.7k	1.1k	707	619	216	5.6k
Kazunori Ohnishi Japan	34	1.8k 0.6×	2.0k 0.8×	723 0.6×	228 0.3×	475 0.8×	219	4.4k
Thomas Büchner Germany	42	7.1k 2.2×	3.8k 1.4×	1.9k 1.6×	817 1.2×	2.4k 3.8×	131	8.7k
Nitin Jain United States	49	3.5k 1.1×	2.4k 0.9×	3.2k 2.8×	295 0.4×	2.3k 3.7×	464	9.7k
Junmin Li China	32	1.2k 0.4×	1.9k 0.7×	318 0.3×	384 0.5×	335 0.5×	189	3.5k
John P. Perentesis United States	39	764 0.2×	1.4k 0.5×	365 0.3×	322 0.5×	818 1.3×	140	4.1k
Tomas Radivoyevitch United States	30	885 0.3×	1.3k 0.5×	904 0.8×	549 0.8×	168 0.3×	156	3.4k
Gail J. Roboz United States	46	5.0k 1.5×	3.6k 1.3×	2.0k 1.8×	576 0.8×	929 1.5×	317	7.6k
Cristina Nanni Italy	49	1.3k 0.4×	1.2k 0.4×	337 0.3×	799 1.1×	139 0.2×	257	7.7k
Michael Kneba Germany	48	2.3k 0.7×	991 0.4×	3.5k 3.0×	339 0.5×	1.8k 2.9×	216	8.1k
Sandip Kumar Roy India	18	324 0.1×	1.1k 0.4×	132 0.1×	107 0.2×	209 0.3×	75	2.5k

Countries citing papers authored by Wen‐Chien Chou

Since Specialization

Citations

This map shows the geographic impact of Wen‐Chien Chou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen‐Chien Chou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen‐Chien Chou more than expected).

Fields of papers citing papers by Wen‐Chien Chou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen‐Chien Chou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen‐Chien Chou. The network helps show where Wen‐Chien Chou may publish in the future.

Co-authorship network of co-authors of Wen‐Chien Chou

This figure shows the co-authorship network connecting the top 25 collaborators of Wen‐Chien Chou. A scholar is included among the top collaborators of Wen‐Chien Chou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen‐Chien Chou. Wen‐Chien Chou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Yu‐Wen, Hao-Yang Lin, Chien‐Chin Lin, et al.. (2025). Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems. Hematological Oncology. 43(1). e70040–e70040.

Ueda, Yasutaka, Wen‐Chien Chou, Yeow Tee Goh, et al.. (2025). Prevention and Management of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria in Asia: A Narrative Review. International Journal of Molecular Sciences. 26(6). 2504–2504. 1 indexed citations

Tsai, Cheng‐Hong, et al.. (2025). Annotation-free deep learning for predicting gene mutations from whole slide images of acute myeloid leukemia. npj Precision Oncology. 9(1). 35–35. 2 indexed citations

Yao, Chi‐Yuan, Li‐Tan Yang, Masaaki Takeuchi, et al.. (2025). Clonal Hematopoiesis Is Associated With Adverse Clinical Outcomes and Left Ventricular Remodeling in Aortic Stenosis. JACC Advances. 4(2). 101532–101532. 1 indexed citations

Lin, Chien‐Chin, Chia‐Lang Hsu, Chi‐Yuan Yao, et al.. (2024). HOPX as a tumour‐suppressive protein in T‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 206(2). 505–516.

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2024). Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms. Blood Cancer Journal. 14(1). 57–57. 7 indexed citations

Yao, Chi‐Yuan, Chien‐Chin Lin, Cheng‐Hong Tsai, et al.. (2024). Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes. Blood Advances. 8(10). 2442–2454. 3 indexed citations

Tsai, Cheng‐Hong, Feng‐Ming Tien, Yuan‐Yeh Kuo, et al.. (2023). Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer Journal. 13(1). 4–4. 17 indexed citations

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2023). Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. American Journal of Hematology. 98(3). 398–407. 6 indexed citations

10.

Yao, Chi‐Yuan, Chien‐Chin Lin, Chi‐Ling Chen, et al.. (2022). Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients. SHILAP Revista de lepidopterología. 3(4). 1209–1219. 4 indexed citations

11.

Chien, Li‐Nien, et al.. (2022). Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: A national population-based analysis from 2001 to 2015. Journal of the Formosan Medical Association. 122(6). 505–513. 9 indexed citations

12.

Yao, Chi‐Yuan, Chien‐Chin Lin, Chia‐Lang Hsu, et al.. (2022). The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression. Journal of the Formosan Medical Association. 122(7). 636–647. 1 indexed citations

13.

Hou, Hsin‐An, et al.. (2021). Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015. Annals of Hematology. 101(1). 109–118. 1 indexed citations

14.

Lin, Chien‐Chin, Chi‐Yuan Yao, Chia‐Lang Hsu, et al.. (2021). Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. British Journal of Haematology. 196(1). 156–168. 3 indexed citations

15.

Huang, Shang‐Yi, Hsiu‐Hsia Lin, Ming Yao, et al.. (2021). Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients. Journal of the Formosan Medical Association. 121(3). 643–651. 1 indexed citations

16.

Wei, Tong‐You Wade, Pei‐Yu Wu, Ting‐Jung Wu, et al.. (2016). Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA. Cancer Research. 77(2). 494–508. 45 indexed citations

17.

Kantarjian, Hagop M., Xavier Thomas, Anna Dmoszyńska, et al.. (2012). Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology. 30(21). 2670–2677. 818 indexed citations breakdown →

18.

Chen, Chien‐Yuan, Liang‐In Lin, Jih‐Luh Tang, et al.. (2007). RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. British Journal of Haematology. 139(3). 405–414. 88 indexed citations

19.

Chou, Wen‐Chien, Jih‐Luh Tang, Liang‐In Lin, et al.. (2006). Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. Cancer Research. 66(6). 3310–3316. 115 indexed citations

20.

Huang, Shang‐Yi, Cheng‐Shyong Chang, Jih‐Luh Tang, et al.. (1998). Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. British Journal of Haematology. 103(4). 1092–1095. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact